证券代码：000516 证券简称：国际医学 公告编号：2024-066 西安国际医学投资股份有限公司 关于2022年限制性股票激励计划第二个解除 限售期解除限售股份上市流通的提示性公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 特别提示： 1、本次符合解除限售条件的激励对象人数：107 人； 2、本次解除限售的限制性股票数量为 2,079,168 股，占目前公司总股本的 0.0920%； 3、本次解除限售的限制性股票的上市流通日为 2024 年 11 月 29 日。 西安国际医学投资股份有限公司（以下简称"公司"）于 2024 年 4 月 24 日 召开第十二届董事会第十五次会议和第十一届监事会第十一次会议，审议通过了 《关于公司 2021 年限制性股票激励计划第三个解除限售期及 2022 年限制性股票 激励计划第二个解除限售期解除限售条件成就的议案》，本次符合解除限售条件 的激励对象共 107 人，可申请解除限售的限制性股票数量为 2,079,168 股，占公司 总股本的 0.0920%。 5、2022 年 11 月 21 日，公司发布了《关于 202 ...

证券代码：000516 证券简称：国际医学 公告编号：2024-065 西安国际医学投资股份有限公司 关于控股股东进行股份质押的公告 1、世纪新元本次股份质押融资不涉及用于满足上市公司生产经营 相关需求。 2、世纪新元未来半年内到期的质押股份累计数量233,350,000股， 占其持有本公司股份总数的37.88%，占公司总股本的10.32%，对应融资 金额为4.02亿元；未来一年内到期的质押股份累计数量402,660,000股， 占其持有本公司股份总数的65.36%，占公司总股本的17.81%，对应融资 金额为7.83亿元。 3、本次股份质押风险在可控范围之内，上述股份质押行为不会导 致公司实际控制权的变更。世纪新元资信状况良好，具备较强的资金偿 还能力，还款资金来源包括投资收益、分红、其他收入等，其质押的股 份现不存在平仓风险，且对公司生产经营、公司治理等不产生实质性影 响。后续如出现平仓风险，将采取包括但不限于提前购回、补充质押等 措施应对风险。 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 西安国际医学投资股份有限公司（以下简称"公司"）近日接到控 股 ...

Investment Rating - The report maintains a "Recommend" rating for International Medical (000516) with a target price of 7.5 RMB, compared to the current price of 5.95 RMB [1] Core Views - The company's Q3 2024 revenue reached 1.186 billion RMB, a 4.58% YoY increase, with a net loss of 39 million RMB [1] - Revenue growth is expected to continue in Q4 due to the peak season for medical services, with potential for profit improvement [1] - The company's profitability remains stable, with a Q3 gross margin of 8.58%, down 2.35 percentage points YoY [1] - Operating expenses improved, with sales expense ratio at 0.64% (-0.06pct), management expense ratio at 11.53% (-1.11pct), and financial expense ratio at 3.50% (-1.25pct) [1] Financial Forecasts - Revenue projections for 2024-2026 are adjusted to 5.106 billion, 5.841 billion, and 6.638 billion RMB, representing YoY growth of 10.6%, 14.4%, and 13.6% respectively [2] - Net profit forecasts for 2024-2026 are -211 million, 5 million, and 173 million RMB [2] - The company's estimated fair value is 16.9 billion RMB based on DCF model [2] Financial Performance - Q1-Q3 2024 revenue reached 3.606 billion RMB, a 7.85% YoY increase, with a net loss of 212 million RMB [1] - The company's total assets are projected to grow from 11.321 billion RMB in 2023 to 14.280 billion RMB in 2026 [6] - Operating cash flow is expected to improve from 684 million RMB in 2024 to 1.439 billion RMB in 2026 [6] Market Performance - The stock has a total market capitalization of 13.449 billion RMB and a circulating market capitalization of 13.222 billion RMB [4] - The stock price has fluctuated between 4.04 RMB and 9.33 RMB over the past 12 months [4] Industry Outlook - The medical services industry is expected to enter a peak season in Q4, potentially driving revenue growth and profit improvement [1] - The company's bed capacity is expected to continue breaking new highs, supporting revenue growth [1]

Investment Rating - The report does not provide a specific investment rating for the company, but it indicates that the industry is expected to follow the market with an overall return between -5% and 5% over the next six months [11]. Core Insights - The company reported a steady revenue growth of 4.6% in Q3 2024, achieving a total revenue of 1.19 billion yuan, while the net profit attributable to shareholders was -40 million yuan, indicating a narrowing loss compared to previous periods [1]. - For the first three quarters of 2024, the company achieved a total revenue of 3.61 billion yuan, reflecting a year-on-year increase of 7.9%, with a net profit of -210 million yuan, which is an improvement of 4.6% year-on-year [1]. - The company has made progress in cost reduction and efficiency improvement, with total expense ratios decreasing by 3.0 percentage points in the first three quarters of 2024 [1]. - The company has established a strategic partnership with Korea's CHA Group to set up China's first referral center, enhancing its academic capabilities and international cooperation [2]. Financial Performance Summary - In Q3 2024, the company achieved a revenue of 1.19 billion yuan, with a year-on-year growth of 4.6% [1]. - The net profit attributable to shareholders for Q1-Q3 2024 was -210 million yuan, showing a year-on-year improvement of 4.6% [1]. - The company’s gross profit margin for the first three quarters was 9.2%, an increase of 0.4 percentage points year-on-year [1]. - The company expects revenues for 2024, 2025, and 2026 to be 5.1 billion yuan, 5.8 billion yuan, and 6.5 billion yuan respectively, with a forecasted return to profitability in 2025 [2][7]. Revenue and Profit Forecast - The report forecasts that the company will achieve revenues of 5.1 billion yuan in 2024, 5.8 billion yuan in 2025, and 6.5 billion yuan in 2026 [2][7]. - The company anticipates that the utilization rate of hospital beds will continue to improve, leading to a gradual realization of scale effects [2][7]. - The report includes key assumptions for revenue growth, including a projected bed utilization rate of 100% in 2024, increasing to 120% by 2026 [6].

证券代码：000516 证券简称：国际医学 公告编号：2024-064 西安国际医学投资股份有限公司 关于股份回购进展公告 本公司及董事会全体成员保证公告内容的真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 西安国际医学投资股份有限公司（以下简称"本公司"或"公司"） 于2024年4月24日召开第十二届董事会第十五次会议，并于2024年5月20 日召开2023年度股东大会，审议通过了《关于回购公司股份方案的议案》 及《关于提请股东大会授权董事会办理本次回购相关事宜的议案》，决 定使用自有资金以集中竞价交易方式回购已发行的人民币普通股（A股） 股票，回购的股份将全部用于注销以减少公司注册资本。本次回购的资 金总额不低于人民币10,000万元（含）且不超过人民币15,000万元（含）， 回购价格不超过人民币9.16元/股（含），具体回购股份的数量以回购 结束时实际回购的股份数量为准。回购期限为自公司股东大会审议通过 本次回购方案之日起12个月内。公司已在中国证券登记结算有限责任公 司深圳分公司开立股份回购专用证券账户。具体内容详见公司分别于 2024年4月26日和5月21日在《中国证券报》《上海证券报》 ...

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected price increase of over 15% in the next 6-12 months [2][10]. Core Insights - The company reported revenue, net profit attributable to shareholders, and net profit excluding non-recurring items for the first three quarters of 2024 at 1.04 billion, 217 million, and 168 million RMB respectively, showing year-on-year growth of 22.38%, 12.03%, and 14.92% [2]. - The company has significantly reduced its net loss attributable to shareholders by 37.2% year-on-year in the first three quarters of 2024, driven by increased patient volume in high-tech and central hospitals [3]. - The company is expected to achieve profitability by 2025 due to scale effects and the expansion of its hospital network, which includes the Xi'an International Medical Center Hospital and the Xi'an High-tech Hospital [3]. Summary by Sections Performance Review - For Q3 2024, the company achieved revenue of 370 million RMB, a year-on-year increase of 25.81%, with net profit attributable to shareholders and net profit excluding non-recurring items growing by 13.40% and 16.72% respectively [2]. - The first three quarters of 2024 saw a revenue growth of 7.85%, attributed to increased outpatient and inpatient numbers [3]. Operational Analysis - The company has established a comprehensive medical service platform and is a member of the Mayo Clinic International, enhancing its service quality [3]. - The strategic framework of "one group + three major hospital areas" and the business model of "comprehensive medical care + specialty" are expected to drive future growth [3]. Profit Forecast and Valuation - The revenue forecast for 2024 and 2025 has been adjusted downwards to 4.9 billion and 5.6 billion RMB, respectively, with a projected revenue of 6.7 billion RMB for 2026 [4]. - The net profit forecast for 2024 has been revised to a loss of 284 million RMB, with a significant reduction in the expected net profit for 2025 [4].

编号：2024-08 1 证券代码： 000516 证券简称： 国际医学 西安国际医学投资股份有限公司 投资者关系活动记录表 | --- | --- | --- | |--------------|-------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

Investment Rating - The report maintains a "Buy" rating for the company [5] Core Views - The company's overall operations are stable, with losses continuing to narrow. In the first three quarters of 2024, the company's revenue reached 3.606 billion, a year-on-year increase of 7.85%. The net profit attributable to the parent company was -212 million, a year-on-year increase of 4.59%. Excluding the impact of selling Shanzhou Hospital last year, the net profit after deducting non-recurring gains and losses was -220 million, a year-on-year increase of 37.20%, indicating a rapid narrowing of losses [8] - The third quarter showed slight fluctuations, but the fourth quarter is expected to achieve a single-quarter turnaround. In Q3, the company's revenue was 1.186 billion, a year-on-year increase of 4.58%, with a slight quarter-on-quarter decline of 4.95% due to seasonal factors. The net profit attributable to the parent company was -39 million, and the net profit after deducting non-recurring gains and losses was -81 million, a year-on-year narrowing of 14.85%. Historically, Q4 is the highest revenue quarter, and with the continued increase in the number of diagnoses and treatments at the central hospital, a turnaround is anticipated in Q4 [8] - Profitability is steadily improving, and scale effects are becoming evident. In the first three quarters of 2024, the company's gross margin and net margin were 9.19% and -8.16%, respectively, both showing year-on-year increases of 0.77 and 0.31 percentage points. The expense ratios for sales, management, finance, and R&D have decreased year-on-year, indicating a continuous scale effect [9] - The company is a comprehensive hospital operation group in Northwest China, with stable operations in its "senior" high-tech hospitals. The central hospital, with a revenue scale of over 10 billion, is entering a fast track of development, and the number of diagnoses and treatments continues to rise, indicating a promising outlook. Revenue forecasts for 2024-2026 are 5.141 billion, 6.152 billion, and 7.524 billion, with net profits of -230 million, -40 million, and 960 million, respectively [9] Summary by Sections - **Financial Performance**: In Q3 2024, the company reported revenue of 1.186 billion, a year-on-year increase of 4.58%, while the net profit attributable to the parent company was -39 million. The first three quarters of 2024 saw total revenue of 3.606 billion, a year-on-year increase of 7.85% [8] - **Profitability Metrics**: The gross margin for the first three quarters was 9.19%, and the net margin was -8.16%, both showing improvements compared to the previous year. The company has successfully reduced its expense ratios across various categories [9] - **Future Outlook**: The company is expected to achieve a turnaround in Q4, with revenue forecasts indicating significant growth in the coming years. The central hospital's development is on a fast track, with increasing treatment volumes anticipated [9]

编号：2024-07 1 证券代码： 000516 证券简称： 国际医学 西安国际医学投资股份有限公司 投资者关系活动记录表 | --- | --- | --- | |--------------|-------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company has shown stable revenue growth, continuously enhancing its operational strength [1] - The company reported total revenue of 3.606 billion yuan for the first three quarters of 2024, representing a year-on-year increase of 7.85%, while the net profit attributable to the parent company was -0.212 billion yuan, an increase of 4.59% [1] - In Q3 alone, the company achieved total revenue of 1.186 billion yuan, up 4.58% year-on-year, and the net profit attributable to the parent company was -0.385 billion yuan, a reduction in loss by 44% compared to Q2 2024 [1] - The company has entered into a strategic cooperation with CHA Medical Group from South Korea to enhance cross-border medical services [1] Financial Performance Summary - The company is expected to achieve total revenues of 5.454 billion yuan, 6.385 billion yuan, and 7.210 billion yuan for the years 2024, 2025, and 2026 respectively, with year-on-year growth rates of 18.1%, 17.1%, and 12.9% [2][5] - The net profit attributable to the parent company is projected to be -0.235 billion yuan, -0.054 billion yuan, and 0.019 billion yuan for the years 2024, 2025, and 2026 respectively, with year-on-year growth rates of 36.2%, 77.0%, and 135.7% [2][5] - The gross profit margin is expected to improve from 10.4% in 2024 to 13.1% in 2026 [2][5] - The company’s operating cash flow is projected to be 1.087 billion yuan in 2024, with a gradual increase in subsequent years [3] Key Financial Ratios - The company’s return on equity (ROE) is expected to improve from -6.4% in 2024 to 0.5% in 2026 [2][5] - The price-to-earnings (P/E) ratio is projected to be 636.05 in 2026, indicating a significant increase in valuation [2][5] - The debt-to-asset ratio is expected to be 68.2% in 2024, slightly increasing to 68.6% in 2026 [5]